Exchange Rates Wipe Out Growth For Abbott’s Established Unit
Unfavorable foreign-exchange effects eradicated any organic growth for Abbott’s Established Pharmaceuticals unit in the second quarter and first half of 2019.
You may also be interested in...
Abbott’s Established Pharmaceuticals business saw double-digit organic growth in the fourth quarter of 2019 on the back of its “unique branded generic strategy in emerging markets,” particularly in Latin America and Asia.
Competitive procurement practices for off-patent molecules in China are not affecting Abbott adversely because its local Established Pharmaceuticals portfolio is focused on niche, hard-to-make branded generics.
Paracetamol, opioids and non-steroidal anti-inflammatory drugs are among the common medicines that “can do more harm than good” and should not be used for managing chronic primary pain, according to a draft NICE guideline.